Clinical Trial Update: Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ribociclib for efficacy in HR+/HER2− advanced breast cancer after progression on CDK4/6 inhibitors has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ribociclib (ribociclib)

Snippet

Sponsor: Melissa K Accordino | Conditions: Metastatic Breast Cancer, Breast Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-12-06